- https://doi.org/10.1016/j.esmoop.2025.105896
A phase IV prospective study of efficacy and safety of ribociclib and letrozole as first-line therapy in older women (≥70 years) with hormone receptor-positive HER2-negative advanced breast cancer: the RibOB study
Abstract
Translate Article 
Take Notes
Translate Article Take Notes A phase IV prospective study of efficacy and safety of ribociclib and letrozole as first-line therapy in older women (≥70 years) with hormone receptor-positive HER2-negative advanced breast cancer: the RibOB study
- Ask R Discovery
- Chat PDF
AI summaries and top papers from 250M+ research sources.
